Published in Nano-Micro Letters , a breakthrough article led by Chunhai Fan (Shanghai Jiao Tong University) introduces acupoint-delivered nanovaccines (ADN) that ignite dual-niche immunological priming. By exploiting ST36 acupoint’s mast-cell-rich microenvironment, ADN simultaneously recruits CD11b⁺ dendritic cells at the injection site and floods draining lymph nodes with 110 nm PEI/OVA nanovaccines—independent of CCR7-mediated DC migration. This strategy delivers 6-fold more OVA-specific CTLs, 5-fold stronger germinal-center responses, and 10 3 -fold higher anti-SARS-CoV-2 IgG titers than intramuscular shots, while completely preventing B16-OVA melanoma in mice.
Why Acupoint Delivery Changes the Game
Engineering the Acupoint Niche
Real-World Efficacy
Future Outlook
Acupoint nanovaccines are poised to redefine precision immunization—turning ancient acupuncture wisdom into a cutting-edge therapeutic reality.
Nano-Micro Letters
Experimental study
Eliciting Dual-Niche Immunological Priming by Acupoint Delivery of Nanovaccines
28-May-2025